NCT06145048View on ClinicalTrials.gov

Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung.

PHASE2CompletedINTERVENTIONAL
Enrollment

89

Participants

Timeline

Start Date

October 5, 2023

Primary Completion Date

October 31, 2024

Study Completion Date

February 20, 2025

Conditions
Lung CancerLung Metastases
Interventions
DRUG

VGT-309

Intravenous drug to be given over 15-20 minutes by syringe pump.

Trial Locations (6)

3065

St. Vincent's Hospital, Melbourne

19104

Hospital of the University of Pennsylvania, Philadelphia

32806

Orlando Health Cancer Institute, Orlando

55905

Mayo Clinic, Rochester

77030

University of Texas MD Anderson Cancer Center, Houston

91010

City of Hope National Medical Center, Duarte

All Listed Sponsors
lead

Vergent Bioscience, Inc.

INDUSTRY

NCT06145048 - Phase 2B Safety and Efficacy Study of VGT-309 in Subjects With Cancer in the Lung. | Biotech Hunter | Biotech Hunter